Catalyst

Slingshot members are tracking this event:

Bellicum Pharma (BLCM) to complete Phase 1 study of BPX-201 Dendritic Cell Vaccine in Metastatic Castrate Resistant Prostate Cancer in May 2017

Source Link:
https://clinicaltrials.gov/ct2/show/NCT01823978?term=bellicum+pharmaceuticals&no_unk=Y&rank=3&submit_fld_opt=

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BLCM
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours
https://clinicaltria...
Additional Relevant Details New Estimated Study Completion Date: May 2017 - Originally expected to read out in May 2016.
https://clinicaltria...
Additional Relevant Details
  •  BPX-201 program to discontinue after current study concludes: Based on the prioritization of our other pipeline opportunities, the Company no longer intends to progress its BPX-201 vaccine into additional studies after the conclusion of the ongoing Phase 1 trial.
http://ir.bellicum.c...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Aug 13, 2015
Occurred Source:
http://ir.bellicum.com/phoenix.zhtml?c=253830&p=irol-newsArticle&ID=2079562
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1, Bpx-201, Dendritic Cell Vaccine, Prostate Cancer, Dose Escalation
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.